Benzinga's Top Upgrades By: Benzinga via Benzinga December 08, 2015 at 09:01 AM EST Analysts at Goldman Sachs upgraded Myriad Genetics, Inc. (NASDAQ: MYGN) from Sell to Neutral. The price target for Myriad Genetics ... Read More >> Related Stocks: Allete Inc Ares Management LP Douglas Emmett Fireeye Inc Hershey Co Kellogg Co Lamar Advertis A Myriad Genetics Inc Wabco Holdings Inc